<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9100095</journal-id>
<journal-id journal-id-type="pubmed-jr-id">8509</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Cell Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Molecular and cellular neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1044-7431</issn>
<issn pub-type="epub">1095-9327</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28549865</article-id>
<article-id pub-id-type="pmc">5516945</article-id>
<article-id pub-id-type="doi">10.1016/j.mcn.2017.05.007</article-id>
<article-id pub-id-type="manuscript">NIHMS880511</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Application of CRISPR/Cas9 to the Study of Brain Development and Neuropsychiatric Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Powell</surname>
<given-names>S.K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gregory</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akbarian</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brennand</surname>
<given-names>K.J.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY, 10029</aff>
<aff id="A2">
<label>2</label>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, 10029</aff>
<aff id="A3">
<label>3</label>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029</aff>
<aff id="A4">
<label>4</label>Instructional Technology Group, Icahn School of Medicine at Mount Sinai, New York, NY, 10029</aff>
<aff id="A5">
<label>5</label>Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 10029</aff>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>82</volume>
<fpage>157</fpage>
<lpage>166</lpage>
<!--elocation-id from pubmed: 10.1016/j.mcn.2017.05.007-->
<abstract>
<p id="P2">CRISPR/Cas9 technology has transformed our abilities to manipulate the genome and epigenome, as applications have expanded from efficient genomic editing to include the targeted localization of effectors to specific genomic loci. By facilitating the manipulation of DNA- and histone-modifying enzyme activities, activation or repression of gene expression, and targeting of transcriptional regulators to defined loci, it is now possible to directly probe the role of gene-regulatory and epigenetic pathways in order to examine their roles in basic biology and disease processes. Here we discuss these emerging CRISPR-based methodologies, with specific consideration of neurobiological applications using human induced pluripotent stem cell (hiPSC)-based models.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>